These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 12122500)

  • 1. Enhanced stability of wild-type and constitutively active alpha(2A)-adrenoceptors by ligands with agonist, silent and inverse agonist properties.
    Pauwels PJ; Tardif S
    Naunyn Schmiedebergs Arch Pharmacol; 2002 Aug; 366(2):134-41. PubMed ID: 12122500
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Facilitation of constitutive alpha(2A)-adrenoceptor activity by both single amino acid mutation (Thr(373)Lys) and g(alphao) protein coexpression: evidence for inverse agonism.
    Pauwels PJ; Tardif S; Wurch T; Colpaert FC
    J Pharmacol Exp Ther; 2000 Feb; 292(2):654-63. PubMed ID: 10640303
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disparate ligand-mediated Ca(2+) responses by wild-type, mutant Ser(200)Ala and Ser(204)Ala alpha(2A)-adrenoceptor: G(alpha15) fusion proteins: evidence for multiple ligand-activation binding sites.
    Pauwels PJ; Colpaert FC
    Br J Pharmacol; 2000 Aug; 130(7):1505-12. PubMed ID: 10928951
    [TBL] [Abstract][Full Text] [Related]  

  • 4. S18616, a highly potent, spiroimidazoline agonist at alpha(2)-adrenoceptors: I. Receptor profile, antinociceptive and hypothermic actions in comparison with dexmedetomidine and clonidine.
    Millan MJ; Dekeyne A; Newman-Tancredi A; Cussac D; Audinot V; Milligan G; Duqueyroix D; Girardon S; Mullot J; Boutin JA; Nicolas JP; Renouard-Try A; Lacoste JM; Cordi A
    J Pharmacol Exp Ther; 2000 Dec; 295(3):1192-205. PubMed ID: 11082457
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Heterogeneous ligand-mediated Ca(++) responses at wt and mutant alpha(2A)-adrenoceptors suggest multiple ligand activation binding sites at the alpha(2A)-adrenoceptor.
    Pauwels PJ; Colpaert FC
    Neuropharmacology; 2000 Aug; 39(11):2101-11. PubMed ID: 10963753
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dissimilar pharmacological responses by a new series of imidazoline derivatives at precoupled and ligand-activated alpha 2A-adrenoceptor states: evidence for effector pathway-dependent differential antagonism.
    Pauwels PJ; Rauly I; Wurch T
    J Pharmacol Exp Ther; 2003 Jun; 305(3):1015-23. PubMed ID: 12649300
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Partial to complete antagonism by putative antagonists at the wild-type alpha(2C)-adrenoceptor based on kinetic analyses of agonist:antagonist interactions.
    Pauwels PJ; Colpaert FC
    Br J Pharmacol; 2000 Dec; 131(7):1385-90. PubMed ID: 11090111
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiparkinsonian agent piribedil displays antagonist properties at native, rat, and cloned, human alpha(2)-adrenoceptors: cellular and functional characterization.
    Millan MJ; Cussac D; Milligan G; Carr C; Audinot V; Gobert A; Lejeune F; Rivet JM; Brocco M; Duqueyroix D; Nicolas JP; Boutin JA; Newman-Tancredi A
    J Pharmacol Exp Ther; 2001 Jun; 297(3):876-87. PubMed ID: 11356907
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bidirectional allosteric effects of agonists and GTP at alpha(2A/D)-adrenoceptors.
    Tian WN; Miller DD; Deth RC
    J Pharmacol Exp Ther; 2000 Feb; 292(2):664-71. PubMed ID: 10640304
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Actions of alpha2 adrenoceptor ligands at alpha2A and 5-HT1A receptors: the antagonist, atipamezole, and the agonist, dexmedetomidine, are highly selective for alpha2A adrenoceptors.
    Newman-Tancredi A; Nicolas JP; Audinot V; Gavaudan S; Verrièle L; Touzard M; Chaput C; Richard N; Millan MJ
    Naunyn Schmiedebergs Arch Pharmacol; 1998 Aug; 358(2):197-206. PubMed ID: 9750005
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Does [3H]2-methoxy-idazoxan (RX 821002) detect more alpha-2-adrenoceptor agonist high-affinity sites than [3H]rauwolscine? A comparison of nine tissues and cell lines.
    Erdbrügger W; Raulf M; Otto T; Michel MC
    J Pharmacol Exp Ther; 1995 Jun; 273(3):1287-94. PubMed ID: 7791100
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evidence for protean agonism of RX 831003 at alpha 2A-adrenoceptors by co-expression with different G alpha protein subunits.
    Pauwels PJ; Rauly I; Wurch T; Colpaert FC
    Neuropharmacology; 2002 May; 42(6):855-63. PubMed ID: 12015212
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multiple alpha 2 adrenergic receptor subtypes. I. Comparison of [3H]RX821002-labeled rat R alpha-2A adrenergic receptors in cerebral cortex to human H alpha2A adrenergic receptor and other populations of alpha-2 adrenergic subtypes.
    Renouard A; Widdowson PS; Millan MJ
    J Pharmacol Exp Ther; 1994 Sep; 270(3):946-57. PubMed ID: 7932207
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modulation of ligand responses by coupling of alpha(2A)-adrenoceptors to diverse G(alpha)-proteins.
    Pauwels PJ; Tardif S; Colpaert FC; Wurch T
    Biochem Pharmacol; 2001 May; 61(9):1079-92. PubMed ID: 11301041
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inverse agonist activity at the alpha(2A)-adrenergic receptor.
    Wade SM; Lan K; Moore DJ; Neubig RR
    Mol Pharmacol; 2001 Mar; 59(3):532-42. PubMed ID: 11179449
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phenoxybenzamine and benextramine, but not 4-diphenylacetoxy-N-[2-chloroethyl]piperidine hydrochloride, display irreversible noncompetitive antagonism at G protein-coupled receptors.
    Bodenstein J; Venter DP; Brink CB
    J Pharmacol Exp Ther; 2005 Aug; 314(2):891-905. PubMed ID: 15857948
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacological characterization and autoradiographic distribution of alpha2-adrenoceptor antagonist [3H]RX 821002 binding sites in the chicken brain.
    Díez-Alarcia R; Pilar-Cuéllar F; Paniagua MA; Meana JJ; Fernández-López A
    Neuroscience; 2006 Aug; 141(1):357-69. PubMed ID: 16697114
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. II. Agonist and antagonist properties at subtypes of dopamine D(2)-like receptor and alpha(1)/alpha(2)-adrenoceptor.
    Newman-Tancredi A; Cussac D; Audinot V; Nicolas JP; De Ceuninck F; Boutin JA; Millan MJ
    J Pharmacol Exp Ther; 2002 Nov; 303(2):805-14. PubMed ID: 12388667
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Homologous regulation of the alpha2C-adrenoceptor subtype in human hepatocarcinoma, HepG2.
    Cayla C; Schaak S; Roquelaine C; Gales C; Quinchon F; Paris H
    Br J Pharmacol; 1999 Jan; 126(1):69-78. PubMed ID: 10051122
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reciprocal modulation of alpha(2A)-adrenoceptor and G(alpha o) protein states as determined by carboxy-terminal mutagenesis of a G(alpha o) protein.
    Wurch T; Okuda J; Pauwels PJ
    Mol Pharmacol; 2001 Oct; 60(4):666-73. PubMed ID: 11562427
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.